Designer Drugs: Bath Salts, Synthetic Cannabinoids, and Synthetic HallucinogensPage 10 of 10

8. References / Quiz Login or Register

Bersani FS, Corazza O, Albano G, et al. (2014). 25C-NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, vol. 2014, Article ID 734749. doi:10.1155/2014/734749. Retrieved October 5, 2015 from http://www.hindawi.com/journals/bmri/2014/734749/.

Brandt SD, King LA, Evans-Brown M. (2014). The new drug phenomenon. Drug Test Analysis 6: 587–97. doi: 10.1002/dta.1686. Retrieved September 29, 2015 from http://onlinelibrary.wiley.com/doi/10.1002/dta.1686/full.

Brents LK, Reichard EE, Zimmerman SM, et al. (2011). Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018. Retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 6(7): e21917. doi:10.1371/journal.pone.0021917. Retrieved October 5, 2015 from http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021917.

Drug Enforcement Administration (DEA). (2013). JWH-018, 1-Pentyl-3-(1-naphthoyl) indole: Synthetic cannabinoid in herbal products. Retrieved August 18, 2015 from http://www.deadiversion.usdoj.gov/drug_chem_info/spice/spice_jwh018.pdf.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2015). Synthetic cathinones drug profile. Retrieved August 27, 2015 from http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones.

Falgiani M, Desai B, Ryan M. (2012). Bath salts intoxication: A case report. Case Reports in Emergency Medicine, vol. 2012, Article ID 976314. doi:10.1155/2012/976314. Retrieved October 5, 2015 from http://www.hindawi.com/journals/criem/2012/976314/.

Hohmann N, Mikus G, Czock D. (2014). Effects and risks associated with novel psychoactive substances: Mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int 2014; 111(9):139–47; DOI: 10.3238/arztebl.2014.0139. Retrieved October 5, 2015 from http://www.aerzteblatt.de/int/archive/article?id=155702.

Johnston LD, O’Malley PM, Miech RA, et al. (2015). Monitoring the Future national survey results on drug use: 1975–2014: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan. Retrieved August 26, 2015 from http://monitoringthefuture.org//pubs/monographs/mtf-overview2014.pdf.

Karch SB. (2015). Cathinone Neurotoxicity (“The “3Ms”). Curr Neuropharmacol. 2015 Jan; 13(1):21–25. doi: 10.2174/1570159X13666141210225009. Retrieved October 5, 2015 from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462040/.

Krasowski MD, Ekins S. (2014). Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. Journal of Cheminformatics 2014, 6:22. doi:10.1186/1758-2946-6-22. Retrieved October 5, 2015 from http://www.jcheminf.com/content/6/1/22.

National Center for Biotechnology Information (NCBI). (2015). Mephedrone. PubChem Open Chemistry Database. Retrieved September 18, 2015 from http://pubchem.ncbi.nlm.nih.gov/compound/45266826#section=Top.

National Institute on Drug Abuse (NIDA). (2015a). The science behind designer drugs. Retrieved September 29, 2015 from http://www.drugabuse.gov/news-events/latest-science/science-behind-designer-drugs.

National Institute on Drug Abuse (NIDA). (2015b). Commonly Abused Drugs Charts. Retrieved August 26, 2015 from http://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts#mdma.

National Institute on Drug Abuse (NIDA). (2015c). “Flakka” (alpha-PVP). Retrieved September 21, 2015 from http://www.drugabuse.gov/emerging-trends/flakka-alpha-pvp.

National Institute on Drug Abuse (NIDA). (2014). Drugs of Abuse. Retrieved October 5, 2015 from http://www.drugabuse.gov/drugs-abuse.

Office of Diversion Control (ODC). Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into Schedule I. Department of Justice, Drug Enforcement Administration. Retrieved August 27, 2015 from http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr1219.htm.

Smith CD, Robert S. (2014). Designer drugs: Update on the management of novel psychoactive substance misuse in the acute care setting. Clin Med August 1, 2014 vol. 14 no. 4 409–415. doi: 10.7861/clinmedicine.14-4-409. Retrieved September 21, 2015 from http://www.clinmed.rcpjournal.org/content/14/4/409.long.

Substance Abuse and Mental Health Administration (SAMHSA). (2014). Hallucinogens. Retrieved October 5, 2015 from http://www.samhsa.gov/atod/hallucinogens.

United Nations Office on Drugs and Crime (UNODC). (2014a). UNODC Early Warning Advisory on New Psychoactive Substances. What are New Psychoactive Substances? Retrieved October 5, 2015 from https://www.unodc.org/LSS/Page/NPS.

United Nations Office on Drugs and Crime (UNODC). (2014b). Substance Groups. Retrieved August 26, 2015 from https://www.unodc.org/LSS/Substance.

Watterson LR, Olive MF. (2014). Synthetic cathinones and their rewarding and reinforcing effects in rodents. Advances in Neuroscience, vol. 2014, Article ID 209875. doi:10.1155/2014/209875. Retrieved September 18, 2015 from http://www.hindawi.com/journals/aneu/2014/209875/.

Weaver MF, John A Hopper JA, et al. (2015). Designer drugs 2015: Assessment and management. Addiction Science & Clinical Practice 2015, 10:8. doi:10.1186/s13722-015-0024-7. Retrieved September 18, 2015 from http://www.ascpjournal.org/content/10/1/8.

You've reached the end of this section